NEW YORK, Nov. 6 — A division of Thermo Electron and Paradigm Genetics have formed a partnership to design new technologies for use in metabolomics, also known as the study of the interactions between small molecules, the companies said on Tuesday.

The companies plan to use chromatography and mass spectrometry systems to develop a new way to identify and validate metabolite biomarkers that they believe may be useful in drug discovery. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.